Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence

Phase 2WithdrawnNCT00204503

The University of Texas Medical Branch, Galveston

Overview

The purpose of this study is to determine if Divalproex Sodium can be used to Treat and Prevent Depression in Patients with Bipolar Disorder who have Comorbid Alcohol Dependence/Abuse.

Over half of all patients with bipolar disorder have comorbid substance abuse. The most common substance of abuse is alcohol, which is most commonly associated with the depressed phase of the illness. Although there are available treatments for bipolar depression, no studies have been done to evaluate efficacy in bipolar patients with comorbid substance abuse disorders. Given the independent open-label evidence for efficacy and safety of divalproex sodium in alcohol abuse and bipolar depression, divalproex sodium is the most likely candidate for potential success in bipolar depressed patients with comorbid alcohol abuse or dependence. The purpose of this study is to determine if Divalproex Sodium can be used to Treat and Prevent Depression in Patients with Bipolar Disorder who have Comorbid Alcohol Dependence/Abuse.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Bipolar I or II Depression and Alcohol Abuse or Dependence

Interventions

Depakote ERDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MADRS \>= 20 at screen and 18 at baseline * YMRS =\< 11 at screen and baseline * DMS-IV criteria for past manic or hypomanic episode based on the SCID * DSM-VI criteria for alcohol dependence or abuse based on the SCID. * Alcohol dependence/abuse confirmed by corroboration from family member * Negative urine pregnancy test Exclusion Criteria: * Inability to give informed consent * Inability to give reliable assessment of alcohol consumption * Evidence of alcohol consumption one week prior to baseline * Liver function tests greater than 3X upper limit of normal at screen * History of active hepatitis or hepatic encephalopathy * History of pancreatitis * History of adverse reaction to divalproex sodium * History of seizure other than directly associated w/prior alcohol withdrawl * History of major head trauma with LOC \> 10 min. or skull fracture * Hisotry of hypertension or neurologic illness * If female, not practicing an effective form of birth control

Locations (1)

University of Texas Medical Branch

Galveston, Texas, United States

Outcomes

Primary Outcomes

Primary Efficacy Measures for this study are: Percent change in MADRS from baseline score to study endpoint; Percent of days heavy drinking from 120 days prescreen to study end point; and Percent of subjects successfully completing outpatient detox.

Secondary Outcomes

Secondary Efficacy Measures for this study are: Percent change in IDS-SR and YMRS from baseline to end of week 16.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.